Last reviewed · How we verify

paracetamol + caffeine

GlaxoSmithKline · Phase 3 active Small molecule

Paracetamol acts as a non-selective inhibitor of COX enzymes, reducing prostaglandin synthesis and thereby decreasing pain and fever, while caffeine acts as a stimulant and analgesic.

Paracetamol acts as a non-selective inhibitor of COX enzymes, reducing prostaglandin synthesis and thereby decreasing pain and fever, while caffeine acts as a stimulant and analgesic. Used for Relief of mild to moderate pain, Reduction of fever.

At a glance

Generic nameparacetamol + caffeine
SponsorGlaxoSmithKline
Drug classAnalgesic
TargetCOX enzymes
ModalitySmall molecule
Therapeutic areaPain management
PhasePhase 3

Mechanism of action

Paracetamol's mechanism of action is not fully understood, but it is thought to involve the inhibition of COX enzymes, which are involved in the synthesis of prostaglandins. Prostaglandins are mediators of pain and inflammation, and by reducing their synthesis, paracetamol is able to decrease pain and fever. Caffeine, on the other hand, acts as a stimulant and analgesic by blocking adenosine receptors in the brain, which can help to increase alertness and reduce pain perception.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: